Medical Cannabis Producer Blossom Genetics Secures Seed Funding
PRESS RELEASE 23 MARCH 2020 – LONDON, UK
London start-up Blossom Genetics Corporation Limited has today announced the completion of an initial pre-seed funding round led by Deepbridge Capital. Blossom Genetics was founded in 2019, by Oliver Davies, Oskar Fletcher and Naeem Dungarwalla, with the aim of utilising their experience of growing and breeding soft fruit to develop medical grade cannabis genetics and products. Blossom Genetics is focused on the research, development and cultivation of pharmaceutical-standard medical cannabis products. The company’s genetic research allows the production of bespoke strains with specific agronomic and pharmaceutical traits, which are increasingly in demand from large and small drug developers.
Blossom Genetics CEO and Co-Founder Oskar Fletcher commented;
“Our mission is to advance medicinal cannabis through scientific research to develop best in class products for our customers. At Blossom, we believe cannabinoids have the power to improve lives. We want to make it easy for patients and healthcare providers to have access to and understand how they can benefit from the use of medical cannabis.
Securing this initial funding from Deepbridge enables us to start our journey with the support of a life sciences specialist VC.”
Dr Savvas Neophytou, Partner and Head of Life Sciences at Deepbridge Capital, added;
“We are delighted to be supporting the Blossom Genetics team via our Seed Enterprise Investment Scheme funding. We have seen numerous cannabis-related start-ups over the years but the experience of the team and their focus on genetic research to develop medical grade cannabis set this team apart.”
For further information:
Oskar Fletcher, CEO, Blossom Genetics Corporation Limited